Dynavax Technologies Corporation (NASDAQ:DVAX) Receives Average Recommendation of “Hold” from Analysts

Dynavax Technologies Corporation (NASDAQ:DVAX) has earned an average rating of “Hold” from the five research firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $24.3333.

DVAX has been the subject of a number of recent analyst reports. William Blair cut Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Wall Street Zen upgraded Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, January 21st.

Insider Transactions at Dynavax Technologies

In other Dynavax Technologies news, COO David F. Novack sold 114,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $15.64, for a total value of $1,782,960.00. Following the completion of the transaction, the chief operating officer owned 63,344 shares of the company’s stock, valued at approximately $990,700.16. This trade represents a 64.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.98% of the company’s stock.

Hedge Funds Weigh In On Dynavax Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DVAX. Hantz Financial Services Inc. lifted its position in Dynavax Technologies by 98.5% during the 4th quarter. Hantz Financial Services Inc. now owns 7,650 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 3,796 shares during the period. Mizuho Markets Americas LLC lifted its holdings in shares of Dynavax Technologies by 7.9% during the fourth quarter. Mizuho Markets Americas LLC now owns 319,443 shares of the biopharmaceutical company’s stock worth $4,913,000 after purchasing an additional 23,500 shares during the period. LSV Asset Management lifted its holdings in shares of Dynavax Technologies by 421.1% during the fourth quarter. LSV Asset Management now owns 46,900 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 37,900 shares during the period. Global Retirement Partners LLC purchased a new stake in Dynavax Technologies in the fourth quarter valued at approximately $43,000. Finally, Leonteq Securities AG acquired a new position in Dynavax Technologies in the 4th quarter worth approximately $47,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

DVAX opened at $15.50 on Thursday. The firm has a market capitalization of $1.82 billion, a PE ratio of -41.89 and a beta of 0.97. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94. The business’s 50-day moving average is $14.03 and its two-hundred day moving average is $11.70. Dynavax Technologies has a 1 year low of $9.20 and a 1 year high of $15.73.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.